Egr2 to the rescue: nanoparticles revitalize natural killer cells in the fight against cancer

EMBO J. 2024 Jul;43(13):2527-2529. doi: 10.1038/s44318-024-00144-y. Epub 2024 Jun 17.


Reversal of tumor-induced natural killer (NK) cell dysfunction remains a major hurdle to overcome for the clinical success of immunotherapies based on NK cells targeting solid tumors. New research in The EMBO Journal identifies the transcription factor early growth response gene 2 (Egr2) and diacylglycerol kinase DGKα as two negative regulators of NK cell dysfunction (Sabag et al, 2024).

MeSH terms

  • Animals
  • Early Growth Response Protein 2* / genetics
  • Early Growth Response Protein 2* / metabolism
  • Humans
  • Killer Cells, Natural* / immunology
  • Nanoparticles* / chemistry
  • Neoplasms* / immunology
  • Neoplasms* / metabolism
  • Neoplasms* / therapy


  • Early Growth Response Protein 2